Neoadjuvant chemotherapy in breast cancer: significantly enhanced response with docetaxel

I. C. Smith, Steven Darryll Heys, A. W. Hutcheon, Iain D Miller, S. Payne, Fiona Jane Gilbert, A. K. Ah-See, O. Eremin, L. G. Walker, T. K. Sarkar, S. P. Eggleton, Keith Nicholas Ogston

Research output: Contribution to journalArticle

638 Citations (Scopus)

Abstract

Purpose: To compare the efficacy of neoadjuvant (NA) docetaxel (DOC) with anthracycline-based therapy and determine the efficacy of NA DOC in patients with breast cancer initially failing to respond to anthracycline-based NA chemotherapy (CT).

Patients and Methods: Patients with large or locally advanced breast cancer received four pulses of cyclophosphamide 1,000 mg/m(2), doxorubicin 50 mg/m(2), vincristine 1.5 mg/m(2), and prednisolone 40 mg (4 x CVAP) for 5 days. Clinical tumor response was assessed. Those who responded (complete response [CR] or partial response [PR]) were randomized to receive further 4 x CVAP or 4 x DOC (100 mg/m(2)). All nonresponders received 4 x DOC.

Results: One hundred sixty-two patients were enrolled; 145 patients completed eight cycles of NA CT. One hundred two patients (66%) achieved a clinical response (PR or CR) after 4 x CVAP. After randomization, 50 patients received 4 x CVAP and 47 patients received 4 x DOC. In patients who received eight cycles of CT, the clinical CR (cCR) and clinical PR (cPR) (94% v 66%) and pathologic CR (pCR) (34% v 16%) response rates were higher (P=.001 and P=.04) in those who received further DOC. Intention-to-treat analysis demonstrated cCR and cPR (85% v 64%; P=.03) and pCR (31% v 15%; P=.06). Axillary lymph node examination revealed residual tumor in 33% of patients who received 8 x CVAP and 38% of patients who received further DOC. In patients who failed to respond to the initial CVAP, 4 x DOC resulted in a cCR and cPR rate of 55% and a pCR rate of 2%. Forty-four percent of these patients had residual tumor within axillary lymph nodes.

Conclusion: NA DOC resulted in substantial improvement in responses to DOC.

Original languageEnglish
Pages (from-to)1456-1466
Number of pages10
JournalJournal of Clinical Oncology
Volume20
Issue number6
DOIs
Publication statusPublished - Mar 2002

Keywords

  • AXILLARY LYMPH-NODES
  • PHASE-II TRIAL
  • PATHOLOGICAL RESPONSE
  • ANTHRACYCLINE-RESISTANT
  • INDUCTION CHEMOTHERAPY
  • MULTIDRUG-RESISTANCE
  • PRIMARY TUMOR
  • THERAPY
  • DOXORUBICIN
  • COMBINATION

Cite this

Smith, I. C., Heys, S. D., Hutcheon, A. W., Miller, I. D., Payne, S., Gilbert, F. J., ... Ogston, K. N. (2002). Neoadjuvant chemotherapy in breast cancer: significantly enhanced response with docetaxel. Journal of Clinical Oncology, 20(6), 1456-1466. https://doi.org/10.1200/JCO.20.6.1456

Neoadjuvant chemotherapy in breast cancer: significantly enhanced response with docetaxel. / Smith, I. C.; Heys, Steven Darryll; Hutcheon, A. W.; Miller, Iain D; Payne, S.; Gilbert, Fiona Jane; Ah-See, A. K.; Eremin, O.; Walker, L. G.; Sarkar, T. K.; Eggleton, S. P.; Ogston, Keith Nicholas.

In: Journal of Clinical Oncology, Vol. 20, No. 6, 03.2002, p. 1456-1466.

Research output: Contribution to journalArticle

Smith, IC, Heys, SD, Hutcheon, AW, Miller, ID, Payne, S, Gilbert, FJ, Ah-See, AK, Eremin, O, Walker, LG, Sarkar, TK, Eggleton, SP & Ogston, KN 2002, 'Neoadjuvant chemotherapy in breast cancer: significantly enhanced response with docetaxel', Journal of Clinical Oncology, vol. 20, no. 6, pp. 1456-1466. https://doi.org/10.1200/JCO.20.6.1456
Smith, I. C. ; Heys, Steven Darryll ; Hutcheon, A. W. ; Miller, Iain D ; Payne, S. ; Gilbert, Fiona Jane ; Ah-See, A. K. ; Eremin, O. ; Walker, L. G. ; Sarkar, T. K. ; Eggleton, S. P. ; Ogston, Keith Nicholas. / Neoadjuvant chemotherapy in breast cancer: significantly enhanced response with docetaxel. In: Journal of Clinical Oncology. 2002 ; Vol. 20, No. 6. pp. 1456-1466.
@article{5e4d8c6bd4344be88a247a5fed80925c,
title = "Neoadjuvant chemotherapy in breast cancer: significantly enhanced response with docetaxel",
abstract = "Purpose: To compare the efficacy of neoadjuvant (NA) docetaxel (DOC) with anthracycline-based therapy and determine the efficacy of NA DOC in patients with breast cancer initially failing to respond to anthracycline-based NA chemotherapy (CT).Patients and Methods: Patients with large or locally advanced breast cancer received four pulses of cyclophosphamide 1,000 mg/m(2), doxorubicin 50 mg/m(2), vincristine 1.5 mg/m(2), and prednisolone 40 mg (4 x CVAP) for 5 days. Clinical tumor response was assessed. Those who responded (complete response [CR] or partial response [PR]) were randomized to receive further 4 x CVAP or 4 x DOC (100 mg/m(2)). All nonresponders received 4 x DOC.Results: One hundred sixty-two patients were enrolled; 145 patients completed eight cycles of NA CT. One hundred two patients (66{\%}) achieved a clinical response (PR or CR) after 4 x CVAP. After randomization, 50 patients received 4 x CVAP and 47 patients received 4 x DOC. In patients who received eight cycles of CT, the clinical CR (cCR) and clinical PR (cPR) (94{\%} v 66{\%}) and pathologic CR (pCR) (34{\%} v 16{\%}) response rates were higher (P=.001 and P=.04) in those who received further DOC. Intention-to-treat analysis demonstrated cCR and cPR (85{\%} v 64{\%}; P=.03) and pCR (31{\%} v 15{\%}; P=.06). Axillary lymph node examination revealed residual tumor in 33{\%} of patients who received 8 x CVAP and 38{\%} of patients who received further DOC. In patients who failed to respond to the initial CVAP, 4 x DOC resulted in a cCR and cPR rate of 55{\%} and a pCR rate of 2{\%}. Forty-four percent of these patients had residual tumor within axillary lymph nodes.Conclusion: NA DOC resulted in substantial improvement in responses to DOC.",
keywords = "AXILLARY LYMPH-NODES, PHASE-II TRIAL, PATHOLOGICAL RESPONSE, ANTHRACYCLINE-RESISTANT, INDUCTION CHEMOTHERAPY, MULTIDRUG-RESISTANCE, PRIMARY TUMOR, THERAPY, DOXORUBICIN, COMBINATION",
author = "Smith, {I. C.} and Heys, {Steven Darryll} and Hutcheon, {A. W.} and Miller, {Iain D} and S. Payne and Gilbert, {Fiona Jane} and Ah-See, {A. K.} and O. Eremin and Walker, {L. G.} and Sarkar, {T. K.} and Eggleton, {S. P.} and Ogston, {Keith Nicholas}",
year = "2002",
month = "3",
doi = "10.1200/JCO.20.6.1456",
language = "English",
volume = "20",
pages = "1456--1466",
journal = "Journal of Clinical Oncology",
issn = "0732-183X",
publisher = "American Society of Clinical Oncology",
number = "6",

}

TY - JOUR

T1 - Neoadjuvant chemotherapy in breast cancer: significantly enhanced response with docetaxel

AU - Smith, I. C.

AU - Heys, Steven Darryll

AU - Hutcheon, A. W.

AU - Miller, Iain D

AU - Payne, S.

AU - Gilbert, Fiona Jane

AU - Ah-See, A. K.

AU - Eremin, O.

AU - Walker, L. G.

AU - Sarkar, T. K.

AU - Eggleton, S. P.

AU - Ogston, Keith Nicholas

PY - 2002/3

Y1 - 2002/3

N2 - Purpose: To compare the efficacy of neoadjuvant (NA) docetaxel (DOC) with anthracycline-based therapy and determine the efficacy of NA DOC in patients with breast cancer initially failing to respond to anthracycline-based NA chemotherapy (CT).Patients and Methods: Patients with large or locally advanced breast cancer received four pulses of cyclophosphamide 1,000 mg/m(2), doxorubicin 50 mg/m(2), vincristine 1.5 mg/m(2), and prednisolone 40 mg (4 x CVAP) for 5 days. Clinical tumor response was assessed. Those who responded (complete response [CR] or partial response [PR]) were randomized to receive further 4 x CVAP or 4 x DOC (100 mg/m(2)). All nonresponders received 4 x DOC.Results: One hundred sixty-two patients were enrolled; 145 patients completed eight cycles of NA CT. One hundred two patients (66%) achieved a clinical response (PR or CR) after 4 x CVAP. After randomization, 50 patients received 4 x CVAP and 47 patients received 4 x DOC. In patients who received eight cycles of CT, the clinical CR (cCR) and clinical PR (cPR) (94% v 66%) and pathologic CR (pCR) (34% v 16%) response rates were higher (P=.001 and P=.04) in those who received further DOC. Intention-to-treat analysis demonstrated cCR and cPR (85% v 64%; P=.03) and pCR (31% v 15%; P=.06). Axillary lymph node examination revealed residual tumor in 33% of patients who received 8 x CVAP and 38% of patients who received further DOC. In patients who failed to respond to the initial CVAP, 4 x DOC resulted in a cCR and cPR rate of 55% and a pCR rate of 2%. Forty-four percent of these patients had residual tumor within axillary lymph nodes.Conclusion: NA DOC resulted in substantial improvement in responses to DOC.

AB - Purpose: To compare the efficacy of neoadjuvant (NA) docetaxel (DOC) with anthracycline-based therapy and determine the efficacy of NA DOC in patients with breast cancer initially failing to respond to anthracycline-based NA chemotherapy (CT).Patients and Methods: Patients with large or locally advanced breast cancer received four pulses of cyclophosphamide 1,000 mg/m(2), doxorubicin 50 mg/m(2), vincristine 1.5 mg/m(2), and prednisolone 40 mg (4 x CVAP) for 5 days. Clinical tumor response was assessed. Those who responded (complete response [CR] or partial response [PR]) were randomized to receive further 4 x CVAP or 4 x DOC (100 mg/m(2)). All nonresponders received 4 x DOC.Results: One hundred sixty-two patients were enrolled; 145 patients completed eight cycles of NA CT. One hundred two patients (66%) achieved a clinical response (PR or CR) after 4 x CVAP. After randomization, 50 patients received 4 x CVAP and 47 patients received 4 x DOC. In patients who received eight cycles of CT, the clinical CR (cCR) and clinical PR (cPR) (94% v 66%) and pathologic CR (pCR) (34% v 16%) response rates were higher (P=.001 and P=.04) in those who received further DOC. Intention-to-treat analysis demonstrated cCR and cPR (85% v 64%; P=.03) and pCR (31% v 15%; P=.06). Axillary lymph node examination revealed residual tumor in 33% of patients who received 8 x CVAP and 38% of patients who received further DOC. In patients who failed to respond to the initial CVAP, 4 x DOC resulted in a cCR and cPR rate of 55% and a pCR rate of 2%. Forty-four percent of these patients had residual tumor within axillary lymph nodes.Conclusion: NA DOC resulted in substantial improvement in responses to DOC.

KW - AXILLARY LYMPH-NODES

KW - PHASE-II TRIAL

KW - PATHOLOGICAL RESPONSE

KW - ANTHRACYCLINE-RESISTANT

KW - INDUCTION CHEMOTHERAPY

KW - MULTIDRUG-RESISTANCE

KW - PRIMARY TUMOR

KW - THERAPY

KW - DOXORUBICIN

KW - COMBINATION

U2 - 10.1200/JCO.20.6.1456

DO - 10.1200/JCO.20.6.1456

M3 - Article

VL - 20

SP - 1456

EP - 1466

JO - Journal of Clinical Oncology

JF - Journal of Clinical Oncology

SN - 0732-183X

IS - 6

ER -